Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.

Lori A Leslie Nilesh Gangan Hiangkiat TanQing Huang

Published in: Current medical research and opinion (2022)

High-risk CLL patients treated with 1 L chemoimmunotherapy have poorer clinical and economic outcomes compared to non-high risk patients. Assessment of genetic risk remains suboptimal.

Keyphrases

chronic lymphocytic leukemia
ejection fraction
newly diagnosed
prognostic factors
metabolic syndrome
gene expression
dna methylation
adipose tissue
skeletal muscle
copy number